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Characterisation of male breast 
cancer: a descriptive biomarker 
study from a large patient series
Matthew P. Humphries1,*, Sreekumar Sundara Rajan1,*, Hedieh Honarpisheh2, Gabor Cserni3, 
Jo Dent4, Laura Fulford5, Lee B. Jordan6, J. Louise Jones7, Rani Kanthan8, Maria Litwiniuk9, 
Anna Di Benedetto10, Marcella Mottolese10, Elena Provenzano11, Sami Shousha12, 
Mark Stephens13, Janina Kulka14, Ian O. Ellis15, Akinwale N. Titloye16, Andrew M. Hanby1, 
Abeer M. Shaaban17 & Valerie Speirs1
Male breast cancer (MBC) is rare. We assembled 446 MBCs on tissue microarrays and assessed 
clinicopathological information, together with data from 15 published studies, totalling 1984 cases. By 
immunohistochemistry we investigated 14 biomarkers (ERα, ERβ1, ERβ2, ERβ5, PR, AR, Bcl-2, HER2, 
p53, E-cadherin, Ki67, survivin, prolactin, FOXA1) for survival impact. The main histological subtype 
in our cohort and combined analyses was ductal (81%, 83%), grade 2; (40%, 44%), respectively. Cases 
were predominantly ERα (84%, 82%) and PR positive (74%, 71%), respectively, with HER2 expression 
being infrequent (2%, 10%), respectively. In our cohort, advanced age (>67) was the strongest 
predictor of overall (OS) and disease free survival (DFS) (p = 0.00001; p = 0.01, respectively). Node 
positivity negatively impacted DFS (p = 0.04). FOXA1 p = 0.005) and AR p = 0.009) were both positively 
prognostic for DFS, remaining upon multivariate analysis. Network analysis showed ERα, AR and 
FOXA1 significantly correlated. In summary, the principle phenotype of MBC was luminal A, ductal, 
grade 2. In ERα+ MBC, only AR had prognostic significance, suggesting AR blockade could be employed 
therapeutically.
With over 1.6 M cases diagnosed in females in 2012 alone, breast cancer is the most common cancer worldwide 
for women1. Significant research has been conducted into its biology and natural history over many decades 
which has helped in our understanding of its biology. Much less studied is male breast cancer (MBC) which 
accounts for around 1% of all breast cancers diagnosed2. For the UK and US this equates to approximately 350 
and 2600 cases annually, respectively3,4. Both the US5 and the UK6 show a gradual increased incidence; 1.0 per 
100 000 in the late 1970 s to around 1.2 per 100 000 at the start of this decade7.
The genesis of MBC is yet to be elucidated fully, with many studies suffering from small number of cases 
available, with published reports on as few 16 cases8. Information derived from these small numbers are at best 
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anecdotal. In the last decade interest in MBC has grown, resulting in accumulation of more substantial numbers of 
cases allowing study of common biomarkers including estrogen receptor (ER) α , progesterone receptor (PR)9–13) 
and human epidermal growth factor receptor 2 (HER2)9–13 as well as less frequently evaluated biomarkers such 
as ERβ 9 androgen receptor (AR)9,10,12–14), Bcl-210,13, p5310,12,13, Ki6710,11,13,15, FOXP114, GCDFP14, NAT116, HLA16, 
MGB14, COX-217, CD3418 and survivin17. BRCA mutations have also been studied19.
Through international collaboration, we accumulated a series of 446 MBC and evaluated and compared their 
clinicopathological characteristics with 15 published studies reporting ≥ 30 MBC cases. Using immunohisto-
chemistry, we evaluated biomarkers with well-established roles in female breast cancer, represented on tissue 
microarrays (TMAs). These included ERβ 1, ERβ 2, ERβ 5, PR, AR, Bcl-2, HER2, p53, E-cadherin, Ki67, survivin, 
prolactin and Forkhead box protein A1 (FOXA1). Our aim was to identify their expression and associate this with 
known clinical or pathological prognostic variables to determine potential prognostic roles in MBC.
Methods
Patients and ethical approval. Leeds (West) Research Ethics Committee granted ethical approval (06/
Q1205/156). TMAs comprising 446 cases were constructed as previously described9. Between 2008 and 2010, 
cases from the UK (59%), Italy (11%), Canada (12%), Nigeria (2%), Hungary (9%) and Poland (7%) were collated 
into nine TMAs. Informed consent was not required as the anonymised material either pre-dated September 
2006, or came from a Research Tissue Bank approved by the UK Human Tissue Authority (15/YH/0025). Under 
the terms of this project-specific ethics (06/Q1206/180), patient identities were not disclosed to the research 
team, hence specific informed consent was not required. Cases were pseudo-anonymised and data were analysed 
anonymously. Treatment details were not available for all cases. Where available, the majority received endocrine 
treatment.
Immunohistochemistry. The antibody panel, selected given their relevance in female breast cancer, is 
shown in Table 1, alongside dilution and retrieval methods and cut-offs. Each biomarker was run as a batch 
with appropriate positive (tissue known to express the biomarker of interest) and negative (no primary anti-
body) controls. Immunohistochemistry was conducted as previously described9, employing REMARK crite-
ria20. Briefly, heat-mediated epitope retrieval was achieved by pressure-cooking in 10% antigen retrieval Access 
Revelation 10X solution at 125 °C (Menarini Diagnostics, UK) or using 1% low pH antigen unmasking solution 
(Vector Laboratories, UK) for 2 minutes. NovolinkTM Polymer Detection System kit was used for visualization 
of primary antibodies following the manufacturer’s instructions (Leica Biosystems, UK). Slides were washed in 
TBST and stained in haematoxylin before dehydration in graded ethanol. Slides were mounted in DPX (Fluka, 
UK). Scoring criteria were selected according to previously reported studies (ER, PR, AR, ERβ 1, ERβ 2, ER β 521, 
FOXA122, prolactin23, Ki6724, E-cadherin25, p5326, Bcl-225, HER227 and survivin28. TMAs were scanned (× 20; 
Aperio ScanScope™ ) then manually scored using ImageScope™ viewing software (Aperio) by MPH and SSR, 
overseen by AMH and AMS, specialised consultant breast histopathologists.
Biomarker associations. A correlation comparison was undertaken to visualise grouping of ERα , PR, AR 
and FOXA1 using Spearman correlation coefficient calculating pairwise combinations. A dataset containing 
scores for these biomarkers was uploaded to TMA Navigator29. Dendograms and correlation networks were gen-
erated providing abstraction of the relationships between multiple markers. Statistical significance was applied to 
identify minimum threshold values. (FDR P-value 0.05). Network significance was determined using algorithm 
AS8930. Benjamini–Yekutieli multiple hypothesis testing was applied.
Statistical analysis. Associations with Disease-free and Overall survival (DFS; from initial diagnosis to the 
diagnosis of local or distant recurrence, OS; from initial diagnosis to death) were analysed (Kaplan–Meier plots, 
log rank test). Hazard ratios were determined by Cox regression. Follow up information was at least 10 years and 
Antibody Clone Dilution Incubation Retrieval Cut-Off
ERα 1D5 1:100 Overnight
High pressure heat retrieval in 
pressure cooker using 1% low pH 
antigen unmasking solution
Allred ≥ 221
FOXA1 ab55718 1:500 Overnight ≥ 422
PR PgR 636 1:200 Overnight Allred ≥ 221
E- cadherin NCH-38 1:100 Overnight > 50%25
Ki67 MIB1 1:100 Overnight > 14%24
p53 DO-7 1:1000 Overnight > 10%26
Bcl-2 124 1:200 Overnight > 10%25
HER2 PN2A 1:25 Overnight 2+ Confirmed by FISH27
Prolactin B6.2 1:3000 Overnight ≥ 323
Survivin D8 1:25 Overnight > 5% (Nuc). ≥ 3 (Cyto)28
AR AR441 1:100 Overnight Allred ≥ 421
ERβ 1 MCA19745 1:20 1 hour
Access revelation
Allred ≥ 321
ERβ 2 MCA 2279 1:20 1 hour Allred ≥ 321
ERβ 5 MCA 46764 A 1:50 1 hour Allred ≥ 321
Table 1.  Antibody dilutions and retrieval methods with scoring cut-offs for dichotomisation.
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was updated in June 2013 and survival periods calculated. Patients were censored at the last day they were known 
to be alive. Variables were entered in univariate and multivariate analysis (Cox proportional hazards regression 
model); these included the biomarker of interest, grade, nodal status and tumour size as is routinely used in anal-
ysis of breast cancer datasets. P values reported for univariate and multivariate analysis were calculated using Cox 
proportional hazards regression model in PASW (v21).
Results
Tumour characteristics. These are illustrated in Table 2, alongside studies published between 1996 and 
2017, which have examined > 30 MBCs. This information was collated to establish the spectrum of MBC data 
reported over the last 2 decades to affirm the representativeness of our cohort, with the combined average of all 
1984 cases presented in the penultimate column of Table 2.
Comparatively our cohort characteristics are virtually identical to those from the combined data. The main 
histological subtype in our cohort and in the combined analyses was ductal (81%, 83%), grade 2 (40%, 44%), 
Feature
1This 
study
Study reference Combined 
data 
excluding 
our study
Combined 
data 
including 
our study
Male Breast 
Cancer 
Pooling 
Project3112 11 10 14 32 16 33 19 34 17 18 35 36 37 38
Number 446 111 91 134 73 145 2202 378 60 58 39 30 65 41 47 46 1538 1984 1328
Histology
 Ductal 359 (81) 99 (89) 86 (95)
121 
(90) 54 (74)
130 
(90)
181 
(82)
283 
(75) 46 (77) 55 (95) 36 (92) 25 (83) 61 (94) 37 (90)
47 
(100) 19 (41) 1280 (83) 1639 (83) 1123 (85)
 Lobular 3 (1) 1 (1) 0 (0) 3 (2) 0 (0) 3 (2) 0 (0) 4 (1) 2 (3) 2 (3) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (2) 16 (1) 19 (1) 18 (1)
 Other 63 (14) 10 (9) 5 (5) 10 (7) 19 (26) 12 (8) 0 (0) 13 (3) 12 (20) 0 (0) 3 (8) 5 (17) 4 (6) 4 (10) 0 (0) 7 (15) 104 (7) 167 (8) 155 (12)
 N/A 21 (5) 1 (1)+ 0 (0) 0 (0) 0 (0) 0 (0) 39 (18)#
78 
(21)# 0 (0) 1 (2)
+ 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 19 (41)# 138 (9) 159 (8) 32 (2)
Grade
 1 48 (11) 14 (13) 2 (2) 32 (24) 14 (19) 35 (24) 15 (7) 33 (9) 2 (3) 7 (12)
25 (64)
1 (3) 9 (14) 1 (2) 8 (17) 4 (9) 202 (13) 250 (13) 292 (22)
 2 177 (40) 62 (56) 54 (59) 54 (40) 45 (62) 64 (44) 98 (45)
153 
(40) 31 (52) 24 (41) 16 (53) 31 (48) 11 (27) 27 (57) 12 (26) 682 (44) 859 (43) 661 (50)
 3 137 (31) 26 (23) 26 (29) 48 (36) 10 (14) 46 (32) 85 (37) 79 (21) 27 (45) 13 (22) 13 (33) 13 (43) 25 (38) 29 (71) 12 (26) 8 (17) 460 (30) 597 (30) 359 (27)
 N/A 84 (19) 9 (8) # 9 (10)+ 0 (0) 4 (5) $ 0 (0) 22 (10)#
113 
(30)# 0 (0)
14 
(24)+ 1 (3)
+ 0 (0) 0 (0) 0 (0) 0 (0) 22 (48)# 194 (13) 278 (14) 16 (1)
Node
 + 134 (30) 68 (61) 41 (45) 61 (46) 26 (36) 66 (46) 78 (35)
105 
(28) 20 (33) 27 (47) 16 (41) 9 (30) 31 (48) 10 (24) 20 (43) 22 (48) 600 (39) 734 (37) 399 (30)
 − 126 (28) 43 (39) 45 (49) 52 (39) 39 (53) 54 (37) 83 (38)
145 
(38) 26 (43) 29 (50) 17 (44) 9 (30) 34 (52) 8 (20) 13 (28) 15 (33) 612 (40) 738 (37) 677 (51)
 N/A 186 (42) 0 (0) 5 (5)
+ 21 
(16)+ 8 (11)
$ 25 
(17)+
59 
(27)#
128 
(34)#
14 
(23)# 2 (3) 
+ 6 (15)+ 12 (40)# 0 (0) 23 (56)
# 14 
(30) # 9 (20 
# 326 (21) 512 (26) 252 (19)
ERα
 + 375 (84)
107 
(96) 88 (97)
125 
(93) 68 (93)
131 
(90)
193 
(88)
245 
(65) 57 (95) 47 (81) 34 (87) 26 (87) 62 (95) 37 (90) 24 (51) 19 (41) 1263 (82) 1638 (83) †
 − 28 (6) 4 (4) 3 (3) 8 (6) 5 (8) 14 (10) 9 (4) 23 (6) 1 (2) 0 (0) 5 (13) 4 (13) 3 (5) 3 (7) 23 (49) 6 (13) 111 (7) 139 (7) †
 N/A 43 (10) 0 (0) 0 (0) 1 (1)$ 0 (0) 0 (0) 18 (8)# 110 (29)# 2 (3)
# 11 
(19)+ 0 (0) 0 (0) 0 (0) 1 (3)
# 0 (0) 21 (46)# 164 (11) 207 (10) †
PR
 + 330 (74) 99 (89) 84 (92) 90 (67) 68 (93) 97 (67)
160 
(73)
224 
(59) 52 (87) 37 (64) 29 (74) 25 (83) 51 (78) 29 (71) 22 (47) 19 (41) 1086 (71) 1416 (71) †
 − 65 (15) 12 (11) 7 (8) 43 (32) 5 (7) 48 (33) 41 (19) 43 (9) 5 (8) 10 (17) 10 (26) 5 (17) 14 (22) 11 (27) 25 (53) 3 (7) 282 (18) 347 (18) †
 N/A 51 (11) 0 (0) 0 (0) 1 (1)$ 0 (0) 0 (0) 19 (8)# 111 (29)# 3 (5)
# 11 
(19)+ 0 (0) 0 (0) 0 (0) 1 (2)
# 0 (0) 24 (52)# 170 (11) 221 (11) †
HER2
 + 7 (2) 9 (8) 13 (14) 4 (3) 1 (1) 5 (3) 18 (8) 55 (15) 5 (8) 2 (3) 4 (10) 3 (10) 6 (9) 18 (44) 0 (0) 7 (15) 150 (10) 157 (8) †
 − 290 (65)
102 
(92) 72 (79)
130 
(97) 68 (93)
140 
(97)
157 
(71)
139 
(37) 50 (83) 17 (29) 35 (90) 27 (90) 56 (86) 22 (54) 0 (0) 10 (22) 1025 (67) 1315 (66) †
 N/A 149 (33) 0 (0) 6 (7)
+ 0 (0) 4 (5) $ 0 (0) 45 (21)#
184 
(49)# 5 (8)
# 39 
(67) + 0 (0) 0 (0) 3 (5)
# 1 (2)# 47 (100)$ 29 (63)
# 363 (24) 512 (26) †
Table 2.  Comparison of clinicopathological features in MBC studies published since 1996 and examining 
>30 cases. 1Includes data from Shaaban et al.9. 2Excludes frozen cases (n = 66). Due to lack of clear definition 
for grade and/or histological subtypes the analysis excludes refs 13, 15, 50, 51 and 52 which examined 77, 58, 
30, 99 and 98 cases, respectively. Numbers in parentheses refer to percentages which were rounded to the 
nearest whole number. N/A refers to data which was not available#, missing+ or not reported$. †These cases were 
stratified into molecular subtypes and hormone receptor status was not reported specifically.
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respectively. Lobular carcinoma was the second most common histology in both cohorts. The “other” category 
included cribriform, papillary, intraductal papillary, micropapillary, mucinous and DCIS. Cases were predomi-
nantly ER (84%, our cohort; 82% combined) and PR positive (74% our cohort; 71%, combined). HER2 expression 
was infrequent in our cohort (2%), and seen in 10% of cases from the combined cohort. Grade break down was 
very similar: grade 1 (11% our cohort; 13% combined), grade 2 (40%, our cohort; 44% combined), grade 3 (31%, 
our cohort 30%; combined). Despite missing/unavailable for grade (19%), node status (42%) and HER2 (33%) 
in our cohort, with the possible exception of node status, this was fairly typical of the other studies, illustrating 
the representativeness of our cohort. While this work was under review, data from the International Male Breast 
Cancer Pooling Project was reported31 and the characteristics of this cohort are presented for comparison in the 
final column of Table 2. Excluding missing data, this further emphasises the similarities of the datasets.
Effect of tumour characteristics and biomarker expression on survival. Tumour characteris-
tics. We performed univariate analysis on the whole cohort (n = 446) and in ERα + cases only (n = 375), con-
sidering the effects of grade, age, lymph node status and tumour size. This is shown in Table 3. Advanced age, 
was the strongest predictor of OS and DFS, both in the whole cohort (HR: 1.05 (1.03–1.08), p = 0.00001; HR: 
1.04 (1.01–1.07), p = 0.01), respectively and in ERα + cases only (HR: 1.07 (1.04–1.10), p = 0.000002; HR: 1.05 
(1.01–1.08), p = 0.004), respectively. Node positivity was significantly associated with DFS in the whole cohort 
(HR: 1.91 (1.03–3.53), p = 0.04) and in ERα + cases (HR: 2.72 (1.30–5.69), p = 0.008).
Biomarkers. ERα , ERβ 1, ERβ 2, ERβ 5, PR, AR, Bcl-2, HER2, p53, E-cadherin, Ki67, survivin, prolactin and 
FOXA1 expression were all evaluated (Table 3). In terms of cellular localisation, ERα , ERβ 1, ERβ 2, ERβ 5, PR, AR, 
Bcl-2, p53, Ki67 and FOXA1 were predominantly nuclear, with characteristic membrane staining seen for HER2 
and E-cadherin. Survivin displayed both nuclear and cytoplasmic staining. Examples are shown in Fig. S1.
In the ERα + cohort, Kaplan Meier survival analysis showed that FOXA1 was significantly associated with bet-
ter OS and DFS (Fig. 1a and b, Log rank p = 0.04; 0.002, respectively), but did not remain upon multivariate anal-
ysis when adjusted for grade, age, size and nodal status (Table 4). AR was significantly associated with improved 
DFS only (Fig. 1c Log rank p = 0.002), that remained significant with multivariate analysis (Table 4; HR: 0.166 
(0.04–0.56), p = 0.004). When evaluated in multivariate analysis with the addition of FOXA1, AR still remained 
independently significant (Table 4; HR: 0.205 (0.04–0.93), p = 0.04). None of the other biomarkers examined 
impacted on survival, and, in the case of survivin, was irrespective of its cellular location.
Feature
Whole cohort (n = 446) ERα+ cases (n = 375)
OS DFS OS DFS
HR (CI) P-value HR (CI) P-value HR (CI) P-value HR (CI) P-value
Grade 1.59 (1.01–2.51) 0.05 0.89 (0.48–1.66) 0.71 1.09 (0.73–1.61) 0.68 0.87 (0.55–1.37) 0.55
Age 1.05 (1.03–1.08) 0.00001 1.04 (1.01–1.07) 0.01 1.07 (1.04–1.10) 0.000002 1.05 (1.01–1.08) 0.004
Node positive 1.24 (0.75–2.08) 0.39 1.91 (1.03–3.53) 0.04 1.17 (0.68–2.01) 0.58 2.72 (1.30–5.69) 0.008
Size (> 20 mm) 1.36 (0.75–2.47) 0.31 1.05 (0.34–2.54) 0.92 1.27 (0.69–2.33) 0.45 1.01 (0.41–2.48) 0.99
ER 1.00 (0.48–2.12) 0.99 1.12 (0.15–8.22) 0.91
AR 0.86 (0.52–1.41) 0.55 0.39 (0.12–0.79) 0.009 0.84 (0.47–1.50) 0.57 0.30 (0.15–0.65) 0.002
ERβ 1 1.15 (0.59–2.25) 0.68 0.91 (0.38–2.16) 0.82 0.87 (0.44–1.71) 0.69 0.91 (0.38–2.16) 0.83
ERβ 2 1.14 (0.58–2.22) 0.71 1.40 (0.50–3.95) 0.52 1.25 (0.60–2.62) 0.56 1.37 (0.49–3.87) 0.55
ERβ 5 0.91 (0.42–2.00) 0.82 0.38 (0.11–1.29) 0.12 2.39 (0.55–10.30) 0.24 0.38 (0.11–1.33) 0.13
FOXA1 0.75 (0.42–1.34) 0.33 0.41 (0.22–0.77) 0.005 0.55 (0.28–0.98) 0.044 0.45 (0.22–0.94) 0.033
PR 1.01 (0.57–1.81) 0.96 0.97 (0.43–2.19) 0.94 1.13 (0.57–2.26) 0.72 0.94 (0.39–2.24) 0.89
Survivin (nuclear) 1.07 (0.67–1.72) 0.782 0.96 (0.52–1.77) 0.89 1.05 (0.64–1.72) 0.86 1.03 (0.54–1.98) 0.93
Survivin 
(cytoplasmic) 0.76 (0.36–1.59) 0.47 0.61 (0.26–1.46) 0.27 0.48 (0.20–1.11) 0.07 0.55 (0.19–1.57) 0.26
Ki67 1.21 (0.72–2.04) 0.46 0.56 (0.27–1.17) 0.12 1.00 (0.57–1.86) 0.99 0.61 (0.28–1.30) 0.20
E-cadherin 1.56 (0.82–2.97) 0.18 0.54 (0.26–1.15) 0.11 1.47 (0.75–2.89) 0.26 0.54 (0.27–1.15) 0.11
Bcl-2 1.13 (0.41–3.12) 0.81 1.02 (0.31–3.38) 0.97 1.04 (0.33–3.35) 0.94 1.00 (0.30–3.33) 0.99
Prolactin 0.98 (0.61–1.59) 0.95 1.04 (0.57–1.88) 0.90 0.99 (0.60–1.65) 0.99 0.93 (0.49–1.79) 0.84
HER2 1.82 (0.25–13.22) 0.56 1.25 (0.30–5.27) 0.76 27.32 (3.19–233.88) 0.003 5.09 (0.63–41.40) 0.13
p53 0.97 (0.52–1.81) 0.91 0.45 (0.17–1.14) 0.09 0.95 (0.49–1.82) 0.87 0.45 (0.17–1.15) 0.09
AR+ FOXA1+ 0.76 (0.35–1.62) 0.43 0.41 (0.16–1.09) 0.08 0.44 (0.19–1.05) 0.06 0.30 (0.10–0.88) 0.03
ERβ 1+ FOXA1+ 22.09 (0.04–11424)) 0.33 1.31 (0.17–9.76) 0.79 20.86 (0.001–604504) 0.56 0.88 (0.21–3.83) 0.87
ERβ 2+ FOXA1+ 22.22 (0.06–7823) 0.30 21.84 (0.004–13372) 0.48 21.11 (0.005–82754) 0.47 21.84 (0.004–133724) 0.49
ERβ 5+ , FOXA1+ 0.31 (0.09–1.06) 0.06 0.11 (0.02–0.68) 0.02 0.24 (0.05–1.01) 0.05 0.11 (0.02–0.68) 0.02
Table 3.  Univariate analysis of clinicopathological features and biomarkers with respect to ERα status. 
Significant P values are in bold. HR = hazard ratio, CI = confidence intervals.
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As FOXA1 is emerging as a critical player in breast cancer biology we examined the impact of its co-expression 
with AR and ERβ isoforms on survival in an ERα + background. Here, co-expression of AR and FOXA1 (Fig. 1e; 
Log rank p = 0.02) was significantly associated with better DFS with a trend towards significance with OS for 
Figure 1. Kaplan-Meier survival analysis. Kaplan-Meier survival analysis showing the impact of FOXA1 
expression on OS (a) and DFS (b), the effect of AR expression on DFS (c) and the impact of AR and FOXA1 co-
expression on OS (d) and DFS (e). The number of at risk patients and events over time are displayed under each 
graph.
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AR and FOXA1 (Fig. 1d; Log rank p = 0.06). ERβ 5 and FOXA1 impacted positively on OS (Table 3; HR: 0.24 
(0.05–1.01), p = 0.05) and DFS (Table 3; HR: 0.11 (0.02–0.68), p = 0.02). However, this was lost on multivariate 
analysis (not shown), where age still remained the strongest predictor of survival.
Network inference using TMA Navigator. Complete scores were available for PR, AR, and FOXA1 in 
220 cases. A correlation comparison was undertaken to visualise the grouping of these biomarkers. The dendo-
gram (Fig. 2a) demonstrates significant correlation between biomarkers using agglomerative hierarchical clus-
tering with complete linkage. This identified ERα , AR and FOXA1 as being significantly correlated within our 
dataset (Fig. 2b). No association between PR and FOXA1 was observed.
Discussion
Efforts towards better understanding the pathobiology of MBC are increasing with a number of groups, including 
our own, starting to accumulate sufficiently large numbers of cases to extend observations from purely anecdotal 
towards improving our knowledge of its underlying biology. Our international collaborative effort makes this one 
of the largest cohorts of MBCs examined to date, examining 446 cases and collating 1540 cases from published 
studies to identify common features of MBC. We do, however, acknowledge its limitations with regard to missing 
patient data and treatment information in some of the cases, despite our best efforts to obtain this.
Comparative analysis of clinicopathological data from our cohort with combined data extracted from 15 stud-
ies published over the last 21 years, reporting ≥ 30 cases10–12,14,16–19,32–38 was investigated totalling 1984 cases. Key 
observations from our cohort were that the majority of patients present with ductal histology, grade 2, with high 
incidence of ER and PR expression, reflective of luminal A phenotype. Nodal positivity was detected in approxi-
mately half of cases where this was known, with HER2 expression being much less frequent in all but one study, 
which reported almost 30% of cases as HER2 positive, which was confirmed by FISH33. Not only were these 
observations reflected in our cohort but they were also observed in the combined data from other studies exclud-
ing our own, which, with the exception of HER2, was very similar to our own cohort, and concurs with recent 
SEER data39. This highlights the representative nature of our cohort for further study. Furthermore, while this 
article was under review, the International Male Breast Cancer Program40 reported clinicopathological features 
of 1328 MBCs, with similar characteristics to our own (Table 2). We acknowledge a weakness of our study is the 
lack of complete information on node status in 41% of cases, despite out best efforts to obtain this. Nevertheless, 
missing node status was the most frequently under-represented variable in the studies outlined in Table 2, aver-
aging 25% attrition, due to missing, unavailable or unreported data, especially in cohorts in excess of 200 cases, 
including those from the International Male Breast Cancer Program16,31,33.
The median age of our cohort was 67 years (range 30–97), in concordance with the average age of diagnosis 
of MBC, which is typically 10 years older than that seen for female breast cancer2. In this respect it is perhaps 
Feature
Whole cohort (n = 446) ERα+ cases (n = 375)
OS DFS OS DFS
HR (CI) P-value HR (CI) P-value 1.22 (0.68–2.17) 0.50 0.93 (0.38–2.27) 0.87
Grade 1.58 (0.81–3.06) 0.18 1.51 (0.49–4.67) 0.47 1.07 (1.03–1.12) 0.00008 1.03 (0.98–1.07) 0.17
Age 1.06 (1.03–1.10) 0.002 1.04 (0.98–1.08) 0.13 1.09 (0.53–2.22) 0.81 2.81 (1.00–7.86) 0.048
Node pos 1.14 (0.57–2.27) 0.70 2.97 (1.04–8.48) 0.042 0.89 (0.43–1.83) 0.75 0.68 (0.24–1.91) 0.47
Size (> 20 mm) 0.99 (0.49–1.99) 0.99 0.56 (0.18–1.71) 0.31 0.51 (0.14–1.78) 0.29 0.30 (0.05–1.73) 0.17
FOXA1 0.50 (0.17–1.48) 0.21 0.26 (0.05–1.37) 0.11 0.51 (0.14–1.78) 0.29 0.30 (0.05–1.73) 0.17
Feature
Whole cohort (n = 446) ERα+ cases (n = 375)
OS DFS OS DFS
HR (CI) P-value HR (CI) P-value 1.20 (0.63–2.18) 0.54 0.61 (0.24–1.51) 0.28
Grade 1.78 (0.90–3.52) 0.09 0.98 (0.32–2.93) 0.97 1.08 (1.03–1.12) 0.00008 1.03 (0.99–1.07) 0.13
Age 1.07 (1.03–1.11) 0.0001 1.03 (0.99–1.07) 0.13 1.07 (0.52–2.18) 0.84 2.58 (0.89–7.49) 0.08
Node pos 1.10 (0.56–2.23) 0.78 2.78 (1.00–7.75) 0.049 0.95 (0.47–1.95) 0.90 0.71 (0.25–1.99) 0.52
Size (> 20 mm) 1.06 (0.52–2.13) 0.87 0.58 (0.19–1.72) 0.33 1.11 (0.45–2.75) 0.81 0.14 (0.03–0.56) 0.005
AR 1.35 (0.54–3.36) 0.51 0.16 (0.04–0.56) 0.004 1.22 (0.66–2.18) 0.54 0.61 (0.24–1.51) 0.288
Feature
Whole cohort (n = 446) ERα+ cases (n = 375)
OS DFS OS DFS
HR (CI) P-value HR (CI) P-value 1.29 (0.62–2.63) 0.48 1.43 (0.41–5.01) 0.568
Grade 1.76 (0.88–3.48) 0.10 1.02 (0.29–3.56) 0.97 1.07 (1.03 1.12) 0.0002 1.05 (0.99–1.12) 0.08
Age 1.06 (1.03–1.10) 0.0002 1.03 (0.99–1.08) 0.12 1.08 (0.48–2.39) 0.84 2.06 (0.66–6.39) 0.20
Node pos 1.08 (0.537–2.176) 0.82 2.85 (0.96–8.49) 0.05 1.23 (0.56–2.70) 0.59 0.56 (0.17–1.84) 0.34
Size (> 20 mm) 0.99 (0.49–2.03) 0.99 0.57 (0.18–1.77) 0.33 0.42 (0.11–2.52) 0.42 0.20 (0.01–2.30) 0.19
AR 1.49 (0.57–3.86) 0.41 0.20 (0.04–0.93) 0.04 1.29 (0.63–2.63) 0.48 1.43 (0.41–5.01) 0.56
FOXA1 0.54 (0.15–1.96) 0.35 0.58 (0.08–4.08) 0.58 0.71 (0.20–2.51) 0.59 0.39 (0.08–1.91) 0.24
Table 4.  Multivariate analysis of clinicopathological features and biomarkers with respect to ERα status. 
Significant P values are in bold. HR  = hazard ratio, CI = confidence intervals.
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unsurprising that our analysis showed that advanced age was the strongest predictor of outcome, as reported in 
female breast cancer where those over 80 years of age had poorer survival, independent of their stage at diagnosis 
or the diagnostic period41. Nodal positivity and AR positivity were negatively prognostic for recurrence, in line 
with other works9.
As MBC is characteristically predominantly ERα -positive we evaluated the effect on outcome in ERα -positive 
cases only (84% of our cohort), investigating several biomarkers for their impact on survival. We found FOXA1 
expression was positively prognostic for both OS and DFS. Often described as a pioneer factor, FOXA1 is emerg-
ing as a critical player in hormone dependent cancer, including breast42 and, in a meta-analysis, has been found 
to be significantly associated with ERα status in female patients43. FOXA1 correlates with survival duration in 
female breast cancer, where cases with high expression had significantly better survival44. Our results corroborate 
these findings for DFS in MBC. Although, this is the first time FOXA1 has been shown to positively impact sur-
vival duration in MBC, this was lost on multivariate analysis.
FOXA1 has the ability to bind to compacted chromatin, making these regions more accessible to other tran-
scription factors, notably ERα and AR45. Since FOXA1 is a major determinant of ERα activity42, we assessed 
the impact of co-expression of FOXA1 with AR and ERβ isoforms. FOXA1 alone and AR expression alone was 
significantly associated with better DFS than ERβ 5 alone. We have previously demonstrated the impact of ERβ 5 
in FBC survival46. While ERβ isoforms have been reported previously in MBC9, these did not impact on survival9. 
Interestingly, ERβ 5 and FOXA1 co-expression showed a significant impact on DFS duration in MBC and showed 
a trend towards significance for OS.
FOXA1 typically works in cooperation with another transcription factor, GATA3. While we did not evaluate 
GATA3 in our work, a previous study has shown GATA3 positivity in only 6 out of 19 MBC (32%), compared 
to 82% of female breast cancer47. Furthermore GATA3 expression did not impact on survival in MBC, unlike 
FBC, where significantly increased mortality was observed. This suggests that the role of GATA3 may not be as 
important a transcription factor in MBC compared with female breast cancer, but further validation is required.
In the current study and previous work (which included 251 of the 446 cases evaluated in this study), AR 
expression was associated with better outcome in MBC9, for DFS but not OS, and this association remained 
upon multivariate analysis. AR is expressed across the main molecular subtypes of breast cancer and is gradually 
becoming recognised as a potential target for therapy in both genders48. Our results confirm these findings and 
could indicate potential use of anti-androgen therapy to treat MBC as demonstrated successfully in a recent 
report49.
Figure 2. Correlative biomarker relationships. Dendrogram showing biomarker correlations using 
agglomerative hierarchical clustering with complete linkage (a) with an example protein network (b) showing 
significant correlation relationships indicated by the thickness of line connections. Nodes range from blue to 
orange, indicating low to high degree of significance, respectively. P values are displayed on the image.
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We also identified a significant correlation of ERα , AR and FOXA1 expression using hierarchical clustering 
and correlation network analysis, with weaker, although still statistically significant, association with PR. We 
previously identified that ERα clustered with AR and ERβ in male but not female breast cancer which clustered 
with ERα and PR9.
In line with our findings, a previous study examining survivin in MBC showed no effect on survival, irrespec-
tive of its cell location17. However, none of the other biomarkers examined influenced outcome in MBC, despite 
showing significance in female breast cancer. This agrees partially with Kornegoor who showed no effect of Bcl2 
on MBC survival but reported that p53 and HER2 were associated with poor survival10. Such disparity could be 
a reflection of cohort size, or potentially may suggest further differences in underlying biology between genders 
which is starting to be illuminated9.
In conclusion, the majority of MBC are luminal A, ductal grade 2 with nodal positivity in approximately half 
of all cases with HER2 expression being rare. While MBC expresses many of the same biomarkers as female breast 
cancer, of those examined, we found only AR remained significant upon multivariate analysis, providing potential 
for AR blockade to be employed therapeutically.
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